OncoMatch/Clinical Trials/NCT05071937
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Is NCT05071937 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including ZEN003694 and Talazoparib for ovarian cancer.
Treatment: ZEN003694 · Talazoparib — This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 any tested
Known BRCA1/2 status
Required: BRCA2 any tested
Known BRCA1/2 status
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: PARP inhibitor — maintenance or therapeutic
Prior therapy with PARPi either as maintenance or therapeutic settings.
Cannot have received: BET inhibitor (ZEN003694)
Have previously received an investigational BET inhibitor (including previous participation in studies with Zenith drug, ZEN003694)
Lab requirements
Blood counts
Hemoglobin 9.0 gm/dL without transfusions during the 4 weeks prior to Screening; ANC 1.5 d7 10^9/L; Platelet count 150,000/mm3
Kidney function
Serum Creatinine 1.5 X ULN
Liver function
AST or ALT 2.0 x ULN or if liver function abnormalities due to liver metastases AST and ALT 5.0 x ULN; Total bilirubin 1.5 x ULN ( 3.0 x ULN for subjects with known Gilbert's syndrome)
Cardiac function
QTcF interval 470 msec
Adequate laboratory parameters at Screening including: Hemoglobin 9.0 gm/dL without transfusions during the 4 weeks prior to Screening; ANC 1.5 d7 10^9/L; Platelet count 150,000/mm3; AST or ALT 2.0 x ULN or if liver function abnormalities due to liver metastases AST and ALT 5.0 x ULN; Total bilirubin 1.5 x ULN ( 3.0 x ULN for subjects with known Gilbert's syndrome); Serum Creatinine 1.5 X ULN; Prothrombin time (PT), INR and PTT < 1.5 x ULN; QTcF interval 470 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pittsburgh Medical Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05071937 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BET inhibitor disqualifies patients from enrollment.
Does this trial require BRCA1?
Yes, BRCA1 any tested is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 any tested is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages